诺和诺德美股盘前下跌3%

Group 1 - The core point of the article is that Novo Nordisk's stock price fell by 3% in pre-market trading due to a significant price reduction of its drug Wegovy in the U.S. [1] - The price of Wegovy has been lowered by 50%, now costing $675 per month [1]